July 14, 2014 / 4:18 PM / in 3 years

BUZZ-U.S. Stocks on the Move-Citigroup, Mylan, Female Health, NIC

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stock indexes rose on Monday, sparked by the latest flurry of merger activity and earnings from Citigroup, putting the S&P 500 on pace to climb for a second straight session. The Dow Jones industrial average was up 0.78 percent at 17,076.28, the S&P 500 was up 0.57 percent at 1,978.71 and the Nasdaq Composite was up 0.68 percent at 4,445.67.

** CITIGROUP INC,$48.524, +3.24 pct

The company said it agreed to pay $7 billion to settle a U.S. government investigation into mortgage-backed securities the bank sold in the run-up to the 2008 financial crisis.

Citigroup on Monday also reported a stronger-than expected adjusted quarterly profit as its fixed-income business performed ahead of forecasts, taking the sting out of the settlement. However, its quarterly profit fell 96 percent.

The stock was one of the top boosts to the S&P 500.

** ENDEAVOUR SILVER, $5.96, -4.03 pct

** MCEWEN MINING, $2.95, -4.84 pct

** FIRST MAJESTIC SILVER CORP, $166.81, +0.23 pct

** SILVER STANDARD RESOURCES, $8.94, -2.72 pct

Gold prices slid more than 2 pct as concerns over euro zone periphery faded. Spot gold was down 2.4 pct at $1,304.90 an ounce at 1310 GMT, on track for its biggest one-day loss since Dec. 2. U.S. gold futures for August delivery were down $31.20 an ounce at $1,306.20. Silver was down 2.3 pct at $20.89 an ounce.

** MYLAN INC, $51.56, +2.71 pct

** ABBOTT LABORATORIES, $41.7, +0.97 pct

Generic drugmaker Mylan said it would buy Abbott’s specialty and branded generics business in developed markets outside the United States in an all-stock transaction valued at about $5.3 billion.

With more than 11.5 million shares traded, Mylan was the fifth most traded stock on the Nasdaq by midday.

** THE FEMALE HEALTH CO, $4.91, -12.01 pct

The company said it would suspend dividend payments to save cash in order to make investments. The company paid a dividend of 7 cents per share in the second quarter.

** HARMONIC INC, $6.37, -10.66 pct

The fiber optics products maker cut its second-quarter revenue forecast, citing delayed orders. The stock fell 11 percent in morning trade, their steepest single-day fall in more than four years.

** PROGENICS PHARMACEUTICALS, $4.67, +10.14 pct

** SALIX PHARMACEUTICALS LTD, $135.67, +10.14 pct

Salix said the U.S. Food and Drug Administration said that Relistor, which has been licensed from Progenics to treat opioid-induced constipation, could be approved on the data submitted on the basis of the data in the in the supplemental new drug application.

Progenics’ stock was among the top percentage gainers on the Nasdaq at 1030 ET.

** KANDI TECHNOLOGIES GROUP INC, $16.5701, +12.57 pct

The China-based electric vehicle maker’s sales from its joint venture in China more than triple to 4,114 electric vehicles in the second quarter from the first quarter.

Kandi’s stock was the third highest percentage gainer on the Nasdaq at 1200 ET, with nearly 12.5 million shares changing hands.

** EXELIXIS INC, $3.7101, +11.58 pct

Exelixis’ experimental drug helped patients with an advanced form of skin cancer live longer without their disease worsening when used in combination with another treatment. The drug, cobimetinib, is being developed in collaboration with Swiss drugmaker Roche AG

** URS CORP, $57.65, +10.82 pct

** AECOM TECHNOLOGY CORP, $34.16, +7.56 pct

Engineering design company Aecom said on Sunday said it would pay about $4 billion to acquire engineering and construction services firm URS.

URS’s stock was the second highest percentage gainer on the NYSE at 1200 ET.

** RIVERBED TECHNOLOGY INC, $19.16, -5.85 pct

The network equipment maker warned that its second-quarter adjusted revenue was lower than its forecast, because of delays in closing some large North American deals.

** NIC INC, $17.51, +10.75 pct

Analysts at Raymond James raised their rating on the outsourcing web portal service provider’s stock to “strong buy” from “outperform”, saying they expect sales and earnings growth to accelerate over the next 12 months.

** WHITING PETROLEUM CORP, $84.37, +7.42 pct

** KODIAK OIL & GAS CORP, $15, +5.41 pct

Whiting said on Sunday it would acquire Kodiak for $3.8 billion in stock, to become the largest producer in North Dakota’s Bakken shale oil formations. The deal is valued at $6 billion and includes Kodiak’s net debt of $2.2 billion.

Brean Capital analysts raised their price target on Whiting’s stock to $102 from $96.

** EXTERRAN HOLDINGS INC, $44.61, +3.48 pct

The natural gas-compression and oilfield equipment services provider’s master limited partnership, Exterran Partners LP EXLP.O, buys natural gas-compression assets from Chesapeake Energy Corp’s unit for about $135 million.

** INTERCEPT PHARMACEUTICALS INC, $229.74, +3.39 pct

Analysts at Deutsche Bank started coverage on stock with “buy” rating, price target of $395, saying they expecetd the company’s experimental liver disease drug, obeticholic acid, to take “meaningful stake” in large non-alcoholic steatohepatitis market.

** PARNELL PHARMACEUTICALS HOLDINGS LTD, $7, +2.19 pct

Jefferies started coverage on the animal health products maker’s stock with a “buy” rating and a $18 price target, saying Parnell is the most attractive play in the sector “given its heavily discounted valuation and strong catalyst set”. Piper Jaffray started coverage with an “overweight” rating and a price target of $17. JMP Securities started coverage with a “market outperform” rating and a price target of $12.

** DORAL FINANCIAL CORP, $7, +2.19 pct

The lender agreed to sell all rights, title and interests in certain residential assets to Abbey Finance Holdings PR LLC for $369 million in cash. (Compiled by Sneha Banerjee in Bangalore; Editing by Savio D‘Souza)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below